Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2022 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma - - Two Partial Responses in Lymphoma and...
November 13, 2019 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results

– Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Nov. 13, 2019 (GLOBE...